Genesis Shareholders OK Spinout of Company ssRNAi Assets into New Firm

As reported by RNAi News earlier this month, the long-struggling Genesis recently received a commitment from Japanese biotech firm MediBic Group to invest up to NZ$1 million ($750,000) in the planned subsidiary, Solirna BioSciences.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.